Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why Catalyst Pharmaceuticals Stock Is Trading Lower

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning.
byHenry Khederian
January 5, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) shares are trading lower by 13% to $14.89 Friday morning. The company announced the pricing of a public offering of 10 million shares of its common stock at $15.00 per share, resulting in total gross proceeds of $150 million.

The underwriters have a 30-day option to purchase an additional 1.5 million shares. The offering, expected to close around January 9 is led by bookrunners BofA Securities, Citigroup, Piper Sandler & Co., Cantor and Truist Securities.

Catalyst intends to use the net proceeds for potential new product candidate acquisitions and general corporate purposes.

See Also: December Jobs Report Topples Expectations

According to data from Benzinga Pro, CPRX has a 52-week high of $22.11 and a 52-week low of $11.09.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

IM Cannabis’ Q4 Revenue: Gross Profit Drops Due To Negative Impact Of Israel-Hamas War, Sees Germany As Growth Opportunity

By Jelena Martinovic
March 28, 11:19 AM
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced on Thursday its financial and operational results for the year ended Dec. 2023. The Toronto-headquartered medical cannabis company with a focus on Israel and Germany reported a 10% year-over-year decrease in revenue to CA$48.8 million ($36 million) in 2023. IM Cannabis attributed it to "negative currency fluctuations and the impact of the Israel-Hamas war on the company's operations." Fourth quarter revenue dropped 26% year-over-year to CA$10.7 million. "As previously warned and as expected, unfortunately, the Israel-Hamas war had a negative impact on our fourth quarter 2023 results, which weighed on our full-year results.," Uri Birenberg, chief financial officer of IMC, said. "Coupled with our fourth quarter of 2023 inventory reduction, the war caused our fourth quarter gross profit to decrease by 68% as compared to the fourth quarter of 2022."

CSE:IMCC